Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 6/2014

01.06.2014 | Head and Neck

Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma

verfasst von: Young-Hoon Joo, Ie-Ryung Yoo, Kwang-Jae Cho, Jun-Ook Park, In-Chul Nam, Chung-Soo Kim, Min-Sik Kim

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

18F-FDG PET/CT is clinically useful in the initial staging and follow-up of patients with head and neck squamous cell carcinoma (HNSCC). We studied the potential prognostic significance of preoperative 18F-FDG PET/CT in HNSCC. The medical records of 294 patients who underwent preoperative 18F-FDG PET/CT for HNSCC were retrospectively reviewed. The median SUVmax of the primary lesions (SUVmax-p) and cervical lymph nodes (SUVmax-n) was 7.98 ± 5.04 (range 1.2–28.7) and 3.34 ± 3.70 (range 1.0–20.4), respectively. There was a significant difference between with and without recurrence in SUVmax-p (11.14 ± 5.36 vs. 6.78 ± 4.35, p < 0.001) and SUVmax-n (5.60 ± 4.22 vs. 1.75 ± 1.46, p < 0.001). The cut-off values of SUVmax-p and SUVmax-n in the context of recurrence and cancer-related death were 8.5 and 3.5. The 5-year disease-free survival of patients with SUVmax-p < 8.5 and SUVmax-n < 3.5 was 79 and 79 %, respectively, whereas that of patients with SUVmax-p ≥ 8.5 and SUVmax-n ≥ 3.5 was 39 and 30 %, respectively. Multivariate analysis confirmed the significant association between 5-year disease-free survival and SUVmax-p ≥ 8.5 (hazard ratio (HR) 2.68, p < 0.001) and SUVmax-n ≥ 3.5 (HR 2.29, p = 0.007). Furthermore, SUVmax-p ≥ 8.5 (HR 3.20, p = 0.012) and SUVmax-n ≥ 3.5 (HR 2.14, p < 0.001) were associated with 5-year overall survival. 18F-FDG PET/CT cut-off values of SUVmax-p ≥ 8.5 or SUVmax-n ≥ 3.5 are associated with a recurrence and survival in HNSCC.
Literatur
1.
Zurück zum Zitat Jain S, Khuri FR, Shin DM (2004) Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer 28:265–286PubMedCrossRef Jain S, Khuri FR, Shin DM (2004) Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer 28:265–286PubMedCrossRef
2.
3.
Zurück zum Zitat Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31:195–201PubMedCrossRef Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31:195–201PubMedCrossRef
4.
Zurück zum Zitat Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF et al (2005) 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 46:1136–1143PubMed Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF et al (2005) 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 46:1136–1143PubMed
5.
Zurück zum Zitat Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM et al (2006) Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 24:4371–4376PubMedCrossRef Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM et al (2006) Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 24:4371–4376PubMedCrossRef
6.
Zurück zum Zitat Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S et al (2003) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015–1024PubMedCrossRef Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S et al (2003) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015–1024PubMedCrossRef
7.
Zurück zum Zitat Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59:1295–1300PubMedCrossRef Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59:1295–1300PubMedCrossRef
8.
Zurück zum Zitat Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY et al (2009) Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 73:764–771PubMedCrossRef Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY et al (2009) Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 73:764–771PubMedCrossRef
9.
Zurück zum Zitat Hoshikawa H, Mitani T, Nishiyama Y, Yamamoto Y, Ohkawa M, Mori N (2009) Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 36:192–198PubMedCrossRef Hoshikawa H, Mitani T, Nishiyama Y, Yamamoto Y, Ohkawa M, Mori N (2009) Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 36:192–198PubMedCrossRef
10.
Zurück zum Zitat Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911PubMed Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911PubMed
11.
Zurück zum Zitat Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199–4208PubMedCrossRef Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199–4208PubMedCrossRef
12.
Zurück zum Zitat Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, el El-Ghazi A, Lehmann W et al (2002) Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20:1398–1404PubMedCrossRef Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, el El-Ghazi A, Lehmann W et al (2002) Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20:1398–1404PubMedCrossRef
13.
Zurück zum Zitat Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY et al (2007) Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48:752–757PubMedCrossRef Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY et al (2007) Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48:752–757PubMedCrossRef
14.
Zurück zum Zitat Zasadny KR, Wahl RL (1993) Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 189:847–850PubMed Zasadny KR, Wahl RL (1993) Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 189:847–850PubMed
15.
Zurück zum Zitat Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843–850PubMedCrossRef Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843–850PubMedCrossRef
16.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK et al (1998) Precisely defining high-risk operable head-and-neck tumors based on RTOG#85-03 and RTOG#88-24: targets for postoperative chemoradiotherapy? Head Neck 20:588–594PubMedCrossRef Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK et al (1998) Precisely defining high-risk operable head-and-neck tumors based on RTOG#85-03 and RTOG#88-24: targets for postoperative chemoradiotherapy? Head Neck 20:588–594PubMedCrossRef
17.
Zurück zum Zitat Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH et al (2001) Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and neck cancer. Int J Radiat Oncol Biol Phys 51:571–578PubMedCrossRef Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH et al (2001) Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and neck cancer. Int J Radiat Oncol Biol Phys 51:571–578PubMedCrossRef
18.
Zurück zum Zitat Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA, Weinstein GS et al (2002) Importance of treatment package time in surgery and postoperative radiation therapy for squamous cell carcinoma of the head and neck. Head Neck 24:115–126PubMedCrossRef Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA, Weinstein GS et al (2002) Importance of treatment package time in surgery and postoperative radiation therapy for squamous cell carcinoma of the head and neck. Head Neck 24:115–126PubMedCrossRef
19.
Zurück zum Zitat Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P et al (2003) SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 44:1044–1050PubMed Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P et al (2003) SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 44:1044–1050PubMed
20.
Zurück zum Zitat Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34:1–6PubMed Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34:1–6PubMed
Metadaten
Titel
Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma
verfasst von
Young-Hoon Joo
Ie-Ryung Yoo
Kwang-Jae Cho
Jun-Ook Park
In-Chul Nam
Chung-Soo Kim
Min-Sik Kim
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 6/2014
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-013-2605-y

Weitere Artikel der Ausgabe 6/2014

European Archives of Oto-Rhino-Laryngology 6/2014 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.